WO2001093837A3 - Protein powder for pulmonary delivery - Google Patents

Protein powder for pulmonary delivery Download PDF

Info

Publication number
WO2001093837A3
WO2001093837A3 PCT/US2001/016472 US0116472W WO0193837A3 WO 2001093837 A3 WO2001093837 A3 WO 2001093837A3 US 0116472 W US0116472 W US 0116472W WO 0193837 A3 WO0193837 A3 WO 0193837A3
Authority
WO
WIPO (PCT)
Prior art keywords
pulmonary delivery
protein powder
particles
surfactant
coated
Prior art date
Application number
PCT/US2001/016472
Other languages
French (fr)
Other versions
WO2001093837A2 (en
Inventor
Meenakshi Ganapati Bhat
George William Cuff
Ronald Keith Wolff
Original Assignee
Lilly Co Eli
Meenakshi Ganapati Bhat
George William Cuff
Ronald Keith Wolff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Meenakshi Ganapati Bhat, George William Cuff, Ronald Keith Wolff filed Critical Lilly Co Eli
Priority to AU2001264789A priority Critical patent/AU2001264789A1/en
Publication of WO2001093837A2 publication Critical patent/WO2001093837A2/en
Publication of WO2001093837A3 publication Critical patent/WO2001093837A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention provides particles of a therapeutic protein core coated with a surfactant that are suitable for pulmonary delivery to the deep lung of a patient in need thereof. Spray drying processes for preparing powders of the core protein particles and powders of the respirable, surfactant-coated, therapeutic protein particles are provided.
PCT/US2001/016472 2000-06-08 2001-05-31 Protein powder for pulmonary delivery WO2001093837A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001264789A AU2001264789A1 (en) 2000-06-08 2001-05-31 Protein powder for pulmonary delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21042300P 2000-06-08 2000-06-08
US60/210,423 2000-06-08

Publications (2)

Publication Number Publication Date
WO2001093837A2 WO2001093837A2 (en) 2001-12-13
WO2001093837A3 true WO2001093837A3 (en) 2002-05-02

Family

ID=22782843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/016472 WO2001093837A2 (en) 2000-06-08 2001-05-31 Protein powder for pulmonary delivery

Country Status (2)

Country Link
AU (1) AU2001264789A1 (en)
WO (1) WO2001093837A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1797902A3 (en) * 2000-12-29 2007-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
DE10114178A1 (en) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinc-free and low-zinc insulin preparations with improved stability
EP1734938B1 (en) 2004-03-26 2012-06-20 Universita' Degli Studi Di Parma Insulin highly respirable microparticles
US7772182B2 (en) 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
WO2008130220A1 (en) * 2007-04-20 2008-10-30 N.V. Nutricia Process for dispersing amino acids
WO2009020434A1 (en) * 2007-08-07 2009-02-12 Nanomaterials Technology Pte Ltd A process for making micro-sized protein particles
KR101820024B1 (en) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 Combination of an insulin and a GLP-1 agonist
US20100183876A1 (en) * 2008-12-23 2010-07-22 Hell Andre Process for the Preparation of a Peptide Powder Form
HUE037735T2 (en) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION COMPRISING desPro36Exendin-4(1-39)-Lys6-NH2 AND METHIONINE
ES2534191T3 (en) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
BR112013004756B1 (en) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland use of ave0010 for the manufacture of a medication for the treatment of type 2 diabetes mellitus
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012171994A1 (en) 2011-06-15 2012-12-20 Novo Nordisk A/S Multi substituted insulins
AR099569A1 (en) 2014-02-28 2016-08-03 Novo Nordisk As INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE
CA2965759C (en) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
JP6970615B2 (en) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Insulin glargine / lixisenatide fixed ratio prescription
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
WO2018116300A1 (en) * 2016-12-22 2018-06-28 Kamada Ltd. Dry powder formulations of alpha-1 antitrypsin
CN113194929B (en) 2018-12-21 2022-12-09 诺和诺德股份有限公司 Spray drying process of GLP-1 peptide

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0634166A1 (en) * 1993-07-15 1995-01-18 Hoechst Aktiengesellschaft Drug compositions containing coated, poorly watersoluble drugs for use in pharmaceutical inhalation forms and method to produce them
WO1996009814A1 (en) * 1994-09-29 1996-04-04 Andaris Limited Spray-dried microparticles as therapeutic vehicles
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO2000012116A1 (en) * 1998-08-28 2000-03-09 Eli Lilly And Company Method for administering insulinotropic peptides
WO2000041682A1 (en) * 1999-01-18 2000-07-20 Lg Chemical Limited Lipophilic microparticles containing a protein drug or antigen and formulation comprising same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0634166A1 (en) * 1993-07-15 1995-01-18 Hoechst Aktiengesellschaft Drug compositions containing coated, poorly watersoluble drugs for use in pharmaceutical inhalation forms and method to produce them
WO1996009814A1 (en) * 1994-09-29 1996-04-04 Andaris Limited Spray-dried microparticles as therapeutic vehicles
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO2000012116A1 (en) * 1998-08-28 2000-03-09 Eli Lilly And Company Method for administering insulinotropic peptides
WO2000041682A1 (en) * 1999-01-18 2000-07-20 Lg Chemical Limited Lipophilic microparticles containing a protein drug or antigen and formulation comprising same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease

Also Published As

Publication number Publication date
AU2001264789A1 (en) 2001-12-17
WO2001093837A2 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
WO2001093837A3 (en) Protein powder for pulmonary delivery
WO2001005429A3 (en) Powder particles with smooth surface for use in inhalation therapy
HK1201447A1 (en) A dry powder formulation and method of making the same and use of the formulation in a dry powder inhaler
HUP0300593A3 (en) Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
WO2005025506A3 (en) Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
WO2002043702A3 (en) Pharmaceutical compositions for inhalation
CA2304819A1 (en) Perforated microparticles and methods of use
DK1294421T3 (en) Dry powder inhaler
SI1402913T1 (en) Dry powder inhalation system for transpulmonary administration, method of manufacturing a dry powdered preparation, and use of a freeze dried composition
YU36302A (en) Novel tiotropium preparation -containing inhalation powder
WO2002080884A3 (en) Powder inhaler formulations
PL360118A1 (en) Continuous dry powder inhaler
WO2005025536A8 (en) Dry powder composition comprising co-jet milled particles for pulmonary inhalation
HK1064313A1 (en) Powder formulation disintegrating system and dry powder inhalers
AUPR894201A0 (en) Respiratory delivery for gene therapy and lentiviral delivery particle
WO2001039745A3 (en) Aerosol composition comprising formoterol
WO2002054868A3 (en) Pulmonary delivery of polyene antifungal agents
WO2004017918A3 (en) Method of preparing dry powder inhalation compositions
WO2005025535A8 (en) Methods for preparing pharmaceutical compositions
HUP0103837A3 (en) Dry powder active agent pulmonary delivery and process for its preparation
CA2461517A1 (en) Nicotine formulations comprising cocoa and use thereof
AU2002316771A1 (en) Guanylate-cyclase c ligand, administered via the airways, for the treatment of respiratory airway problems
AU4717299A (en) Nasal delivery of sildenafil citrate
IL142506A0 (en) Dispersions, a process for preparing them and their use in the preparation of coating mixtures
WO2003090715A3 (en) Particulate materials

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP